Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy

European Urology

Volumn 65, Issue 5, 2014, Pages 875-883

  Mulders, Peter F A ^a   Molina, Arturo ^b   Marberger, Michael ^c   Saad, Fred ^d   Higano, Celestia S ^e   Chi, Kim N ^f   Li, Jinhui ^g   Kheoh, Thian ^b   Haqq, Christopher M ^b   Fizazi, Karim ^h  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^h INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Abiraterone acetate; Elderly; Metastatic castration resistant prostate cancer

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; MINERALOCORTICOID; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GERIATRIC PATIENT; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SIDE EFFECT; TACHYCARDIA; URINARY TRACT INFECTION; VERY ELDERLY; VOMITING;

ABIRATERONE ACETATE; ELDERLY; METASTATIC CASTRATION-RESISTANT PROSTATE CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FATIGUE; HUMANS; HYPERTENSION; HYPOKALEMIA; MALE; MIDDLE AGED; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; STEROID 17-ALPHA-HYDROXYLASE; SURVIVAL RATE; TAXOIDS;

EID: 84896390589     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.09.005     Document Type: Article

References (34)

1. United Nations Department of Economic and Social Affairs Population Division World population prospects: the 2010 revision, highlights and advance tables 2010 United Nations New York, NY
2. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
3. E. Scosyrev, E.M. Messing, S. Mohile, D. Golijanin, and G. Wu Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality Cancer 118 2012 3062 3070
4. S. Sajid, S.G. Mohile, R. Szmulewitz, E. Posadas, and W. Dale Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum Semin Oncol 38 2011 309 325
5. A.R. Shelke, and S.G. Mohile Treating prostate cancer in elderly men: how does aging affect the outcome? Curr Treat Options Oncol 12 2011 263 275
6. C. Falci, E. Morello, and J.P. Droz Treatment of prostate cancer in unfit senior adult patients Cancer Treat Rev 35 2009 522 527
7. S.G. Mohile, K. Bylow, and W. Dale et al. A pilot study of the Vulnerable Elders Survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation Cancer 109 2007 802 810
8. S.K. Bechis, P.R. Carroll, and M.R. Cooperberg Impact of age at diagnosis on prostate cancer treatment and survival J Clin Oncol 29 2011 235 241
9. P.O. Bosset, L. Albiges, and T. Seisen et al. Current role of diethylstilbestrol in the management of advanced prostate cancer BJU Int 110 2012 E826 E829
10. J.S. de Bono, C.J. Logothetis, and A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
11. K. Fizazi, H.I. Scher, and A. Molina et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
12. Harland S, de Bono JS, Haqq C, et al. Abiraterone acetate improves functional status in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: results from the COU-AA-301 phase 3 study. Paper presented at: European Multidisciplinary Cancer Congress (ECCO ESMO ESTRO); September 23-26, 2011; Stockholm, Sweden.
13. C.J. Logothetis, E. Basch, and A. Molina et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol 13 2012 1210 1217
14. C.N. Sternberg, A. Molina, and S. North et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy Ann Oncol 24 2013 1017 1025
15. A. Italiano, C. Ortholan, and S. Oudard et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer Eur Urol 55 2009 1368 1376
16. M.D. Galsky, and N.J. Vogelzang Docetaxel-based combination therapy for castration-resistant prostate cancer Ann Oncol 21 2010 2135 2144
17. M. Shelley, C. Harrison, B. Coles, J. Staffurth, T.J. Wilt, and M.D. Mason Chemotherapy for hormone-refractory prostate cancer Cochrane Database Syst Rev 2006 CD005247
18. S. Halabi, N.J. Vogelzang, S.S. Ou, W.K. Kelly, and E.J. Small Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies J Urol 176 2006 81 86
19. A.J. Armstrong, M.A. Eisenberger, and S. Halabi et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer Eur Urol 61 2012 549 559
20. H.I. Scher, M.J. Morris, E. Basch, and G. Heller End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice J Clin Oncol 29 2011 3695 3704
21. R. Nayyar, N. Sharma, and N.P. Gupta Prognostic factors affecting progression and survival in metastatic prostate cancer Urol Int 84 2010 159 163
22. Impact on abiraterone pharmacokinetics and safety: open-label drug-drug interaction studies with ketoconazole and rifampicin. Paper presented at: European Cancer Congress; September 27-October 1, 2013; Amsterdam, The Netherlands.
23. K.N. Chi, A. Tolcher, and P. Lee et al. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer Cancer Chemother Pharmacol 71 2013 237 244
24. T.M. Beer, W. Berry, E.M. Wersinger, and L.B. Bland Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years Clin Prostate Cancer 2 2003 167 172
25. D.P. Petrylak, C.M. Tangen, and M.H. Hussain et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
26. V.J. Sinibaldi Docetaxel treatment in the elderly patient with hormone refractory prostate cancer Clin Interv Aging 2 2007 555 560
27. I.F. Tannock, W.R. de, and W.R. Berry et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
28. D.R. Berthold, G.R. Pond, F. Soban, W.R. de, M. Eisenberger, and I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
29. J.S. de Bono, S. Oudard, and M. Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
30. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
31. Sternberg CN. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Paper presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; February 14-16, 2013; Orlando, FL, USA.
32. A.O. Sartor, D. Heinrich, and J.M. O'Sullivan et al. Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: a phase III randomized trial (ALSYMPCA) [abstract] J Clin Oncol 30 2012 4551
33. P.W. Kantoff, C.S. Higano, and N.D. Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
34. G.J. Bubley, M. Carducci, and W. Dahut et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467